LRMR earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -1.91. Updated 2026-07-23.
Larimar Therapeutics (LRMR) Research Hub
Larimar Therapeutics (LRMR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.24 USD (-4.68%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.91, market cap 0.34B. This hub links to the full technical, earnings and options research available for LRMR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.24 USD (-4.68%) |
| 52-week range | 1.915 USD – 4.47 USD |
| Trend regime | Range |
| 14-day RSI | 33.2 (Bearish) |
| Trailing P/E | -1.91 |
| Market cap | 0.34B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for LRMR
Covered Call on LRMR: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LRMR: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LRMR: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
LRMR technical analysis: range, last 2.24 USD, RSI 33.2, 52w range 1.915 USD–4.47 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LRMR in?
Larimar Therapeutics (LRMR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LRMR in an uptrend or downtrend?
As of 2026-10-26, LRMR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LRMR's trailing P/E ratio?
LRMR's trailing P/E is -1.91, with a market cap of 0.34B. See the earnings research page for full valuation detail.
When does LRMR next report earnings?
LRMR is next scheduled to report earnings on 2026-08-13.